Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you decide on first line treatment for a patient with metastatic colon cancer with dMMR, a HER2 mutation and no mutations in KRAS or BRAF?
Related Questions
Would you offer zolbetuximab in a non-Asian population?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
When treating rectal cancer with TNT and induction chemotherapy first, do you repeat pelvic MRI prior to planning for chemoradiation?
How would you approach treatment of a patient with adenocarcinoma of unknown primary only found in a left supraclavicular lymph node?
Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?
Would you offer chemoRT to a colon cancer case with a resected polyp with positive margins if the patient wishes to avoid surgery?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
What are your top takeaways from ASCO GI 2025?
Do you regularly perform pharmacogenomic testing for patients prior to starting chemotherapy?
Would you consider the use of EGFR inhibition (cetuximab/panitumumab) in first line in metastatic right-sided RAS/RAF WT colon cancer, if bevacizumab contraindicated?
